With close ties to Dartmouth College, the firm designated as Stealth Biologics was in receipt of Phase I of the NIH STTR funded project - that firm being one of three involved in redesigning and re-engineering therapeutic proteins to evade immune recognition: designated Engineering immunotolerance®. Stealth Biologics® is a specialized service company that employs an advanced Deimmunized By Design® computational platform to assess and mitigate immunogenicity risk for biopharma clients. Phase II was subsequently awarded to Lyticon - describes as "advancing a portfolio of high-value anti-infective biologics towards commercialization in diverse market segments, including clinical translation of breakthrough biotherapies for life-threatening bacterial infections" The two entities (and a third indicated as named Occulo Bio) with all three firms clearly part of the same operation) The proprietary technology as funded is designed seamlessly to integrate advanced computational models, global optimization algorithms, and protein engineering methodologies to design and develop highly active therapeutic candidates that exhibit reduced immunogenicity. Phase II is awarded to Lyticon - new startup established by one of the Stealth principals but focused on advancing biotech solutions to the antimicrobial drug-resistance crisis.
